Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$680M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
UnitedHealth
UNH
|
+$393M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$381M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$348M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.24B |
| 2 |
Tesla
TSLA
|
+$450M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$444M |
| 4 |
TSMC
TSM
|
+$432M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.79% |
| 2 | Consumer Discretionary | 0.82% |
| 3 | Financials | 0.79% |
| 4 | Healthcare | 0.66% |
| 5 | Industrials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
STRR
12251
DELISTED
Star Equity Holdings
STRR
| $30K | ﹤0.01% |
+15,067
| New | +$32K |
|
12252
Telomir Pharmaceuticals
TELO
$81.2M
| $29.8K | ﹤0.01% |
23,817
+118
| +0.5% | +$273 |
|
12253
PUT
Atossa Therapeutics
ATOS
$26.7M
| $29.7K | ﹤0.01% |
2,387
-220
| -8% | -$2.63K |
|
12254
BioAtla
BCAB
$5.43M
| $29.6K | ﹤0.01% |
1,496
+822
| +122% | +$16.7K |
|
12255
PUT
Citius Pharmaceuticals
CTXR
$16.6M
| $29.3K | ﹤0.01% |
+18,400
| New | +$16.9K |
|
12256
CALL
LanzaTech
LNZA
$87.2M
| $29.2K | ﹤0.01% |
1,081
| – | – |
|
12257
CALL
Apyx Medical
APYX
$131M
| $29K | ﹤0.01% |
+12,900
| New | +$18.2K |
|
|
CIRC
12258
Circle8 Group
CIRC
$67M
| $28.7K | ﹤0.01% |
+14,154
| New | +$42.6K |
|
|
MLGO
12259
CALL
MicroAlgo
MLGO
$45.4M
| $28.7K | ﹤0.01% |
+1,873
| New | +$306K |
|
12260
PUT
Goldgroup Mining
GORO
$292M
| $28.5K | ﹤0.01% |
+46,800
| New | +$25.5K |
|
|
ISRLW
12261
DELISTED
Israel Acquisitions Corp Warrant
ISRLW
| $28.5K | ﹤0.01% |
128,190
-42,523
| -25% | -$7.31K |
|
|
TSBX
12262
DELISTED
Turnstone Biologics
TSBX
| $28.5K | ﹤0.01% |
79,305
+54,000
| +213% | +$18.9K |
|
|
LRE
12263
Lead Real Estate
LRE
$17.9M
| $28.1K | ﹤0.01% |
+15,665
| New | +$22.7K |
|
12264
PUT
Inovio Pharmaceuticals
INO
$133M
| $27.9K | ﹤0.01% |
+13,700
| New | +$26.3K |
|
|
LNAI
12265
CALL
Lunai Bioworks
LNAI
$9.97M
| $27.7K | ﹤0.01% |
1,195
+27
| +2% | +$754 |
|
12266
PUT
Nkarta
NKTX
$194M
| $27.7K | ﹤0.01% |
+16,700
| New | +$30.6K |
|
|
HEPS
12267
CALL
D-Market Electronic Services & Trading
HEPS
$965M
| $27.3K | ﹤0.01% |
10,100
| – | – |
|
|
CRDL
12268
Cardiol Therapeutics
CRDL
$234M
| $27.2K | ﹤0.01% |
+20,023
| New | +$23.3K |
|
12269
PUT
CEL-SCI Corp
CVM
$26M
| $27K | ﹤0.01% |
11,800
+10,930
| +1,256% | +$57.2K |
|
12270
CALL
Pacific Biosciences
PACB
$472M
| $26.9K | ﹤0.01% |
21,700
-1,434,400
| -99% | -$1.66M |
|
12271
PUT
Outlook Therapeutics
OTLK
$155M
| $26.9K | ﹤0.01% |
16,800
-600
| -3% | -$957 |
|
12272
PUT
Lightwave Logic
LWLG
$916M
| $26.7K | ﹤0.01% |
21,500
-156,900
| -88% | -$165K |
|
|
ORIO
12273
PUT
Orion Digital Corp
ORIO
$19.8M
| $26.5K | ﹤0.01% |
21,000
-1,200
| -5% | -$1.36K |
|
12274
Xtant Medical Holdings
XTNT
$44.9M
| $26.2K | ﹤0.01% |
35,440
-71,683
| -67% | -$40.8K |
|
|
LGO
12275
Largo
LGO
$77.4M
| $26K | ﹤0.01% |
+20,010
| New | +$28K |
|
Similar funds
Jeff Yass's Q2 2025 Portfolio in Review
As of Q2 2025, Jeff Yass held 14,080 positions worth $720B, up 23% from $586B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass deployed $32.3B of net new capital in Q2 2025, opening 1,720 new positions and adding to 5,716 existing holdings. Its largest new stake was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
By sector, the portfolio is most concentrated in Technology at 1.8% of assets, up from 1.6% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $5.24B trimmed.
- Jeff Yass's largest Q2 2025 buy was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
- Jeff Yass added most to Apple in Q2 2025, an estimated $680M increase.
- Jeff Yass's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.24B.
- Jeff Yass fully exited Vanguard Intermediate-Term Bond ETF in Q2 2025, selling an estimated $61.8M.
- Jeff Yass's ten largest holdings make up 26% of its $720B portfolio in Q2 2025.
- Jeff Yass opened 1,720 new positions and closed 1,538 in Q2 2025.
- Jeff Yass's portfolio value rose 23% quarter-over-quarter to $720B.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.